NCT00796133已完成2 期
A Phase 2, Dose-finding, Cross-over Study to Evaluate the Effect of a NES/E2 Transdermal Gel Delivery on Ovulation Suppression in Normal Ovulating Women
Population Council3 个研究点 分布在 3 个国家目标入组 18 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
- 试验地点
- 3
- 主要终点
- Determine with ultrasound scan (USS) measures and serum progesterone (P) assessment the lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles
研究概览
简要总结
This is a Phase 2, dose-finding, cross-over study for the purposes of evaluating the effect of a NES/E2 transdermal gel delivery on ovulation suppression in normal ovulating women.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Woman is between 18 and 40 years of age
- •Has intact uterus and ovaries
- •Has regular menstrual cycles of 25-35 days duration
- •Able to comply with the protocol, including frequent blood sampling, and lives within the catchment area of the clinic
- •Understands the study procedures and agrees to participate in the study by giving written informed consent
- •Able to use non-hormonal, double-barrier contraceptives (e.g. condoms and diaphragm) with every act of intercourse, or has been sterilized with tubal ligation, or only male partner has been sterilized with vasectomy
- •Progesterone >10 nmol/L in at least one sample in the lead-in cycle
排除标准
- •All contraindications to OC use including
- •Thrombophlebitis or thromboembolic disorders
- •Past history of deep vein thrombophlebitis or thromboembolic disorders
- •Past or current cerebrovascular or coronary artery disease
- •Known or suspected carcinoma of the breast
- •Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- •Undiagnosed abnormal genital bleeding
- •Cholestatic jaundice of pregnancy or jaundice with prior pill use
- •Hepatic adenomas or carcinomas
- •Woman has a history of headaches with focal neurological symptoms
- •Known or suspected pregnancy
- •Aged >35 and smoker
- •Positive urine pregnancy test at the screening or baseline visit
- •Desired pregnancy within the duration of the study
- •Known hypersensitivity to progestins
- •Known hypersensitivity to estrogen
- •Undiagnosed vaginal discharge or vaginal lesions or abnormalities
- •In accordance with the Bethesda system of classification Women with a current abnormal Pap smear suggestive of high-grade pre cancerous lesion(s), including HGSIL, are excluded
- •Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity >CIN I is present and/or endocervical curettage is negative
- •Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded if treatment is indicated In accordance with other Pap class systems
- •Women with high grade dysplasia are excluded
- •Women with low grade dysplasia or CIN I interpretation on Pap smear may participate based on investigator discretion in accordance with local standard of care
- •Breastfeeding
- •Cancer (past history of any carcinoma or sarcoma)
- •History of a significant psychiatric disorder, including severe depression.
- •Chronic or acute liver or renal disease
- •Hypertension-- controlled by medication or defined by diastolic BP 85 mm Hg or systolic BP 135mm Hg after 15 minutes rest
- •Dermatitis, psoriasis or other severe skin disorder
- •Known or suspected alcoholism or drug abuse
- •Clinically significant abnormalities of laboratory safety tests
- •Chronic disease or history of illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject
- •Woman is participating or has participated in another clinical study (involving an investigational drug) within one month prior to enrollment.
- •Use of injectable contraceptives during the previous 3 months (e.g. cyclofem) or 9 months (e.g. DMPA)
- •Use of oral contraceptives within the past 1 month
- •Use of concomitant drugs that may interact with the study drugs
研究组 & 干预措施
1
Active Comparator
0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
干预措施: NES/E2 gel (Drug)
3
Active Comparator
1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
干预措施: NES/E2 gel (Drug)
2
Active Comparator
1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
干预措施: NES/E2 gel (Drug)
结局指标
主要结局
Determine with ultrasound scan (USS) measures and serum progesterone (P) assessment the lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles
时间窗: Subjects will remain in the study for approximately 8 months
次要结局
- Evaluate the safety and tolerability of the formulations(Subjects will remain in the study for approximately 8 months)
- Determine with USS and E2 serum levels the dose that can suppress follicle growth and replace estradiol at the physiological early follicular phase level(Subjects will remain in the study for approximately 8 months)
- Evaluate the correlation of NES and E2 serum levels with the percentage of ovulation suppression(Subjects will remain in the study for approximately 8 months)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's DiseaseMild Cognitive ImpairmentDementiaNCT05104463CuraSen Therapeutics, Inc.64
进行中（未招募）
不适用
This is a clinical study designed to explore the safety, effectiveness and optimum dose of the medicine MED-563 in adult patients who suffer from asthma that is not fully controlled by other treatmentsncontrolled AsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020126-17-BGAstraZeneca AB482
撤回
2 期
A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)Freezing of Gait Symptoms in Parkinson's DiseaseNCT04935762CuraSen Therapeutics, Inc.
招募中
2 期
Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac SurgeryCardiac Surgery Associated - Acute Kidney InjuryNCT06632613EnnovaBio200
Unknown
1 期
Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaMultiple MyelomaNCT01792102Oncotherapeutics38